DOMINANT DRUGS FROM SANOFI-AVENTIS, GLAXOSMITHKLINE, AND PFIZER WILL LOSE SIGNIFICANT SHARE TO NOVEL AGENTS IN THE VENOUS THROMBOEMBOLISM TREATMENT AND PROPHYLAXIS MARKETS

Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite the increasing use of low-molecular-weight heparins, including drugs from Sanofi-Aventis, GlaxoSmithKline, and Pfizer, the market dominance of these therapies in the treatment and prophylaxis of venous thromboembolism will be significantly eroded by novel agents over the 2005-2015 forecast period.

PR Newswire (http://sev.prnewswire.com/medical-pharmaceuticals/20060926/NETU00926092006-1.html)